Biotech stocks rise on expectation of pro-industry FDA policy

Markets will price in a 15%+ increase in biotech valuations by December 2026, anticipating a pro-industry FDA stance under a new commissioner. This reflects pharma leaders' lobbying success in shaping regulatory tone.

Implied probability (Yes)

60%